CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations

BackgroundAfatinib is a potent, irreversible second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non-small cell lung cancer (NSCLC) patients harboring either common or uncommon EGFR mutations. However, data on its activity a...

Full description

Bibliographic Details
Main Authors: Liping Kang, Jianliang Mai, Weiting Liang, Qihua Zou, Caiwen Huang, Yongbin Lin, Ying Liang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
NSCLC
afatinib
brain metastases
CNS efficacy
uncommon EGFR mutations
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1094195/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1094195/full

Similar Items